Cutting just one year from the Food and Drug Administration's drug review process could create more than $10 trillion in economic value while getting lifesaving medicines to patients faster, according to a new report calling for major FDA reforms.The report, The Multi-Trillion Dollar Opportunity in Reforming the FDA, published by the free-market policy group Unleash Prosperity, argues that lengthy effectiveness reviews, not safety testing, account for much of the agency's approval timeline. Its authors estimate that trimming those reviews by one year would accelerate patient access to new trea...
HALO NEWSLETTER
Join HALO today and unlock this story instantly — It's Free